Surmodics announces data from SWING trial discussed at ISET

Surmodics announced that the differentiated capabilities of its crystalline drug release, CDR, platform for sirolimus-coated balloons, SCBs, were discussed in connection with 12-month data from the Company’s SWING trial at the 35th annual International Symposium on Endovascular Therapy, ISET, in Miami, Florida. The SWING trial is a first-in-human feasibility study of the Company’s Sundance SCB. At ISET, SWING co-lead investigator Professor Ramon Varcoe, MBBS, MS, FRACS, PHD, MMed, reinforced key findings from the SWING trial. Twelve-month data from the 35 patients enrolled in the trial showed no perioperative deaths or major amputations at 30 days, and just one major re-intervention was reported among the trial subjects, and use of the Sundance SCB was associated with primary patency maintained at 12 months in 80% of the per protocol analysis population. "The technical benefits of CDR are clearly evident via in vivo animal models, which show that the Sundance SCB provides enhanced drug transfer and enables longer drug retention in tissue at therapeutic levels compared with competitor SCBs," said Prof. Varcoe. "The positive 12-month data from SWING suggest that the Sundance SCB’s CDR platform holds significant promise for treating real-world PAD patients."